| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,294 | 0,412 | 08:53 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:06 | NFL Biosciences Issues Share Subscription Warrants and Grants Them Free of Charge to All Shareholders | 212 | Business Wire | The Transaction is structured in two stages: A Warrants: Each existing share entitles its holder to one A Warrant (BSA A), exercisable from November 24 to December 17, 2026. Three A Warrants... ► Artikel lesen | |
| 08:06 | NFL Biosciences Announces Enrollment of the First Participant in Its Phase 2 Tonic Study Evaluating NFL-102 for Smoking and Nicotine Cessation | 179 | Business Wire | Effective start of the clinical trial with the enrolment of the first participant in Part A, involving 40 smokers
First clinical evaluation of NFL-102 in smokers wishing to quit
Initial... ► Artikel lesen | |
| Fr | NFL Biosciences Strengthens Its Intellectual Property With a New Patent Application for NFL-102 | 326 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing immunotherapies for the treatment of tobacco dependence, announces the filing... ► Artikel lesen | |
| 30.10. | NFL Biosciences will participate in the BIO-Europe 2026 conference to continue discussions with potential partners regarding NFL-101 and NFL-102 | 321 | Business Wire | A strategic opportunity to advance ongoing discussions
Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing immunotherapies for... ► Artikel lesen | |
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.10. | NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation | 527 | Business Wire | NFL-101 immunotherapy aimed at reducing neuroinflammation: Biomarker results supporting a personalized medicine approach Next step: discussions with the FDA and EMA to confirm... ► Artikel lesen | |
| 22.10. | NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation | 561 | Business Wire | The TONIC Phase 2 trial evaluating NFL-102 consists of Part A (the first 40 participants) and Part B (the next 270 participants) Enrollment of the first participants (Part A) is scheduled... ► Artikel lesen | |
| 06.10. | NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation | 372 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, provides an update on progress... ► Artikel lesen | |
| 08.09. | NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie | 366 | Business Wire | Oral presentation selected by the SFT 2026 dedicated to the predictive biomarker associated with NFL-101 efficacy in smoking cessation Presentation of the results of a post-hoc analysis... ► Artikel lesen | |
| 28.07. | NFL Biosciences submits phase 2 smoking cessation trial to regulators | 1 | Investing.com | ||
| 28.07. | NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation | 489 | Business Wire | A Phase 2 clinical trial involving 310 smokers, designed to confirm the safety profile of NFL-102, determine its optimal dose, and evaluate its efficacy An adaptive design that allows for... ► Artikel lesen | |
| 07.07. | International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102 | 687 | Business Wire | Strengthening the international scientific recognition of NFL Biosciences' tobacco franchise within the leading scientific community dedicated to nicotine and tobacco research Oral presentation... ► Artikel lesen | |
| 30.06. | NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain | 454 | Business Wire | Validation of the entire GMP manufacturing chain for NFL-102, from extract production through to the lyophilized finished drug product Confirmation of NFL Biosciences' industrial capacity... ► Artikel lesen | |
| 01.06. | NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation | 384 | Business Wire | Identification of a biomarker predictive of efficacy, enabling a personalized approach to smoking cessation with NFL-101 In the target population, efficacy approximately 30% higher than... ► Artikel lesen | |
| 25.05. | NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application | 650 | Business Wire | Personalized medicine approach that could represent a first in smoking cessation Biomarker rooted in NFL-101's immunomodulatory mechanism of action Rigorous analytical validation... ► Artikel lesen | |
| 11.05. | NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101 | 414 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL, a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies... ► Artikel lesen | |
| 04.05. | NFL Biosciences: International Scientific Community's Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences | 470 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces that... ► Artikel lesen | |
| 15.04. | NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation | 616 | Business Wire | Emergence of a new paradigm in smoking cessation, based on an in-depth understanding of the biological mechanisms of addiction, with the ambition to achieve superior efficacy compared with current... ► Artikel lesen | |
| 15.04. | NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors | 675 | Business Wire | A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company Cash runway is immediately extended until the third... ► Artikel lesen | |
| 07.04. | A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video | 443 | Business Wire | A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse An educational video illustrating... ► Artikel lesen | |
| 11.03. | Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan | 648 | Business Wire | €500,000 loan with a 36-month repayment deferral Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |